Literature DB >> 12096198

Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma.

R I Ketchell1, M D'Amato, M W Jensen, B J O'Connor.   

Abstract

BACKGROUND: Cysteinyl leukotrienes (cysteinyl-LTs) have been implicated in the pathogenesis of allergen induced airway responses. Airway responsiveness (AR) to inhaled cysteinyl-LTs is dramatically increased following allergen challenge in animal studies. The effect in man has not been evaluated.
METHODS: Ten mild steroid-naïve asthmatic subjects with an isolated early asthmatic response (EAR) and 21 with an additional late asthmatic response (LAR) took part in a randomised controlled crossover study to assess AR to inhaled methacholine (MCh) and cysteinyl-LT D(4) (LTD(4)) 22 and 24 hours, respectively, after allergen challenge. Eight subjects had two further LTD(4) challenges separated by a 2 week washout period to assess the reproducibility of inhaled LTD(4) challenge.
RESULTS: In subjects with an isolated EAR, non-significant mean (SE) increases in AR of 0.4 (0.4) doubling doses (DD) for MCh and 0.4 (0.5) DD for LTD(4) followed allergen challenge compared with control. A significant correlation between AR to MCh and LTD(4) followed both control (r=0.91, 95% CI 0.67 to 0.98; p=0.0002) and allergen challenge (r=0.79, 95% CI 0.32 to 0.95; p=0.0063). In subjects with an additional LAR there was a significant increase in AR to MCh (1.2 (0.3) DD, p=0.0005) following allergen challenge but no overall effect on AR to LTD(4) (0.69 (0.4) DD, p=0.11). A significant correlation between AR to MCh and LTD(4) was again observed (r=0.70; 95% CI 0.38 to 0.87; p=0.0004) following control, although it was reduced following allergen challenge (r=0.48; 95% CI 0.063 to 0.76; p=0.027). LTD(4) challenge was highly reproducible with a mean difference of 0.2 (0.3) DD between challenges.
CONCLUSIONS: Allergen challenge significantly increases AR to inhaled MCh but not to LTD(4) in subjects with LAR. The lack of a comparable increase in AR to LTD(4) is surprising. Endogenous cysteinyl-LTs are produced in abundance following allergen challenge and may enhance AR to MCh or induce a degree of tachyphylaxis to LTD(4).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096198      PMCID: PMC1746387          DOI: 10.1136/thorax.57.7.575

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  30 in total

1.  Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics.

Authors:  G M Gauvreau; J M Lee; R M Watson; A M Irani; L B Schwartz; P M O'Byrne
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

2.  Selective airway responsiveness in asthma.

Authors:  B J O'Connor; S D Crowther; J F Costello; J Morley
Journal:  Trends Pharmacol Sci       Date:  1999-01       Impact factor: 14.819

Review 3.  Late asthmatic responses.

Authors:  P M O'Byrne; J Dolovich; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1987-09

4.  Changes in bronchial responsiveness to histamine at intervals after allergen challenge.

Authors:  D W Cockcroft; K Y Murdock
Journal:  Thorax       Date:  1987-04       Impact factor: 9.139

5.  The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects.

Authors:  J P Arm; B W Spur; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1988-10       Impact factor: 10.793

6.  Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects.

Authors:  M G Kaye; L J Smith
Journal:  Am Rev Respir Dis       Date:  1990-04

7.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions.

Authors:  J G De Monchy; H F Kauffman; P Venge; G H Koëter; H M Jansen; H J Sluiter; K De Vries
Journal:  Am Rev Respir Dis       Date:  1985-03

8.  Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls.

Authors:  E Adelroth; M M Morris; F E Hargreave; P M O'Byrne
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

9.  Characterization of the airway response to inhaled leukotriene D4 in normal subjects.

Authors:  R Kern; L J Smith; R Patterson; R D Krell; P R Bernstein
Journal:  Am Rev Respir Dis       Date:  1986-06

10.  The effect of inhaled leukotriene D4 in humans.

Authors:  L J Smith; P A Greenberger; R Patterson; R D Krell; P R Bernstein
Journal:  Am Rev Respir Dis       Date:  1985-03
View more
  5 in total

Review 1.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  Bhupendrasinh F Chauhan; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis.

Authors:  P Gyllfors; M Kumlin; S-E Dahlén; F Gaber; P-O Ehrs; B Dahlén
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

3.  Imaging Inflammation in Asthma: Real Time, Differential Tracking of Human Neutrophil and Eosinophil Migration in Allergen Challenged, Atopic Asthmatics in Vivo.

Authors:  Joanna J Lukawska; Lefteris Livieratos; Barbara M Sawyer; Tak Lee; Michael O'Doherty; Philip J Blower; Martin Kofi; James R Ballinger; Christopher J Corrigan; Gopinath Gnanasegaran; Ehsan Sharif-Paghaleh; Gregory E D Mullen
Journal:  EBioMedicine       Date:  2014-10-28       Impact factor: 8.143

Review 4.  Odd couple: The unexpected partnership of glucocorticoid hormones and cysteinyl-leukotrienes in the extrinsic regulation of murine bone-marrow eosinopoiesis.

Authors:  Pedro Xavier-Elsas; Daniela Masid-de-Brito; Bruno Marques Vieira; Maria Ignez C Gaspar-Elsas
Journal:  World J Exp Med       Date:  2017-02-20

5.  Relationship between atopy and bronchial hyperresponsiveness.

Authors:  Dong In Suh; Young Yull Koh
Journal:  Allergy Asthma Immunol Res       Date:  2013-02-27       Impact factor: 5.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.